Navigation Links
Drug fights cystic fibrosis
Date:2/5/2008

BIRMINGHAM, Ala. An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).

The new study is the latest on a compound called PTC124, which helps to rescue faulty proteins that lead to illnesses. The drug holds promise in treating more than 2,400 genetic diseases caused by a certain class of DNA mutation.

In the UAB tests performed on mice, PTC124 restored to normal function up to 29 percent of the cases of abnormal cystic-fibrosis (CF) protein.

The findings are published in the online version of the journal Proceedings of the National Academy of Sciences and will soon appear in a print edition.

The study adds to research published last year in the journal Nature, which showed PTC124 restored up to 25 percent of the missing or abnormal protein function in mice with Duchenne muscular dystrophy.

Our study shows strong pre-clinical evidence that PTC124 is capable of suppressing nonsense mutations that cause cystic fibrosis, said David Bedwell, Ph.D., professor in the UAB Department of Microbiology and lead author on the study. We think this provides strong evidence for clinical trials with PTC124 in CF patients with this kind of mutation.

A gene that carries a nonsense mutation produces a shortened or faulty protein that degrades in the body. The absence of that protein is what leads to disease, Bedwell said. An estimated one-third of gene defects responsible for human disease are thought to come from nonsense mutations. In the case of CF, the absence of a certain protein leads to an imbalance of salt and water in the linings of the lungs and other membranes.

The UAB study showed that PTC124 allowed the protein to be made in mouse cells where it was previously absent, and it was delivered in a specific location that helped restore salt and water balance in membranes.


'/>"/>
Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. MIT radar technology fights breast cancer
2. New Drug Fights Medication-Linked Bone Loss
3. Experimental Drug Fights Prostate Cancer
4. Connecticut Girl Fights Rare Neurological Disease
5. Two-Drug Combo Fights Brain Tumors
6. Guacamole: Fights Hunger, Cholesterol and Cancer
7. Secondhand Smoke Worsens Lung Function in Cystic Fibrosis Patients
8. Cystic Fibrosis Foundation reports upward trend for key health outcomes
9. Montana Passes Newborn Screening Law for Cystic Fibrosis
10. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
11. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... WEST PALM BEACH, Fla. , Feb. 9 /PRNewswire-USNewswire/ ... a grant awarded to the School District of Palm ... eat right and get fit. The Robert Wood Johnson Foundation ... opportunities for physical activity and access to affordable healthy foods ... and Palm Springs communities. Based on a rigorous ...
(Date:2/9/2010)... iPhone application created by UH researchers is providing ... world. Those annual rankings of America,s fattest and ... host of indirect indicators may soon have a ... the University of Houston provides objective data. , ... from Apple,s "App Store," allows users to keep ...
(Date:2/9/2010)... increased in infants born prematurely in the US, according ... System (LUHS). These findings were reported at the 30th ... Chicago. They also were published in the latest issue ... . , Researchers reported that CP is associated with ... This inflammation is more common in premature births from ...
(Date:2/9/2010)... type II audit is a significant achievement and differentiates ... , ... (PRWEB) February 9, 2010 ... announced that it has successfully completed a Statement on Auditing ... by McGladrey & Pullen, LLP and covered Hallmark Insights operational ...
(Date:2/9/2010)... men with fewer complications, study finds , , TUESDAY, Feb. ... are more likely than men to fail catheter ablation ... procedures five times as often as women and usually ... February issue of HeartRhythm Journal , are based ... and 2008. They underwent pulmonary vein antrum isolation, a ...
Breaking Medicine News(10 mins):Health News:Planting Seeds to Fight Childhood Obesity 2Health News:Phone app providing real-time statistics on physical activity around the world 2Health News:Phone app providing real-time statistics on physical activity around the world 3Health News:Incidence of cerebal palsy on rise in United States 2Health News:Hallmark Insights Completes SAS 70 Type II Audit 2
... Three studies to be presented at Teenage Cancer Trust,s Fifth ... (Monday) have thrown light on the extent of delays that ... with cancer, and on some of the reasons why this ... Cancer at the University of Manchester, UK, will tell the ...
... to 75 with type 2 disease have same odds for condition, ... adults with type 2 diabetes run much less risk than previously ... to the heart, according to a new study. , ... diabetes run the same risk of having a cardiac condition whether ...
... presenting with one checked for other , , SATURDAY, ... between type 2 diabetes and obstructive sleep apnea (OSA) ... the International Diabetes Federation warns. , Up to 40 ... also have diabetes, recent studies suggest. Likewise, more than ...
... Echocardiography System to Acquire, Instantaneous, Non-Stitched Full-Volume Images of the ... ... Heartbeat, TORONTO, June 7 Siemens Healthcare, (http://www.usa.siemens.com/healthcare ) ... the world to acquire,non-stitched, real-time full-volume 3D images of the heart ...
... Event Becomes "Susan G. Komen GLOBAL Race for ... National Mall was,passionately pink this morning, as nearly ... for the 19th annual Susan,G. Komen National Race ... to fund breast cancer research and community health ...
... Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the ... of China ("PRC"),today announced the successful completion of ... May 29, 2008., Tianma pills, one of ... the treatment of headaches. The primary,active ingredient in ...
Other Medicine News:Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 2Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 3Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 4Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2Health News:Doctors Urged to Look for Link Between Type 2 Diabetes, Sleep Apnea 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 3Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 2Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 3
(Date:2/9/2010)... February 9 Debiopharm ... companies with,a focus on the development of ... announced the signature of an exclusive licence ... commercialisation of Debio 025,(alisporivir), a selective, first-in-class ... virus (HCV) effect. The product is currently ...
(Date:2/8/2010)... , Feb. 8 Cost reductions ... Products (Nasdaq: AHPI ) narrowly back into profitability ... Sales for the quarter ended December 31, 2009 ... million during the same quarter last year to ... Allied,s costs of sales were reduced even more sharply, ...
(Date:2/8/2010)... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... for the fourth quarter and year-end 2009 following the ... 2010 . ,, Paul Hamelin , President ... Officer, will host an investment community conference call beginning ... February 26, 2010 to discuss these results and ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Impact Factor names Cell top research journal 8967 1Rotary Marks Progress in Drive to Eradicate Polio 49766 1Rotary Marks Progress in Drive to Eradicate Polio 49766 2Rotary Marks Progress in Drive to Eradicate Polio 49766 3ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 1ASAP Systems Launches New Depreciation Feature Enabling its Customers to Develop Custom Formulas to Calculate Depreciation Of Their Fixed Assets Inven 49762 2
... Therapeutics Limited,one of the UK,s leading pre-IPO biotechnology ... study with its oral, once-daily experimental,cancer therapy CHR-2797 ... (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM),who ... chemotherapy., Headline data from the study, which ...
... CARLOS, Calif., Dec. 12 Nuvelo, Inc.,(Nasdaq: ... patient in a Phase 2,proof-of-concept trial of alfimeprase ... has also been granted fast track designation by ... in this indication. Fast,track designation, which was mandated ...
Other Medicine Technology:Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 3Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 4
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
... Off-white free flowing powder. pH: pH(4.7%, ... Casein Peptone: 24% Yeast Extract: 47% Potassium Phosphate ... To Use: Dissolve 47 gm powder per liter ... of plasmid DNA and recombinant proteins than LB ...
...
Medicine Products: